These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 29277808)

  • 1. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
    Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
    Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
    Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Artaç M
    Eur J Clin Pharmacol; 2024 Jun; 80(6):941-947. PubMed ID: 38478093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
    Appleman LJ; Kim SE; Harris WB; Pal SK; Pins MR; Kolesar J; Agarwal N; Parikh RA; Vaena DA; Ryan CW; Hashmi M; Costello BA; Cella D; Dutcher JP; DiPaola RS; Haas NB; Wagner LI; Carducci MA
    J Clin Oncol; 2024 Jun; 42(17):2061-2070. PubMed ID: 38531002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Karlin N; Sideras K; Morris JC; McIver B; Hay I; Fatourechi V; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Cher Goh B; Isham CR; Harris P; Erlichman C;
    J Clin Endocrinol Metab; 2014 May; 99(5):1687-93. PubMed ID: 24606083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
    Pili R; Qin R; Flynn PJ; Picus J; Millward M; Ho WM; Pitot H; Tan W; Miles KM; Erlichman C; Vaishampayan U
    Clin Genitourin Cancer; 2013 Dec; 11(4):477-83. PubMed ID: 23891158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
    Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
    Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.
    Rinchai D; Verzoni E; Huber V; Cova A; Squarcina P; De Cecco L; de Braud F; Ratta R; Dugo M; Lalli L; Vallacchi V; Rodolfo M; Roelands J; Castelli C; Chaussabel D; Procopio G; Bedognetti D; Rivoltini L
    Clin Transl Med; 2021 Jun; 11(6):e434. PubMed ID: 34185403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
    Jung KS; Lee SJ; Park SH; Lee JL; Lee SH; Lim JY; Kang JH; Lee S; Rha SY; Lee KH; Kim HY; Lim HY
    Cancer Res Treat; 2018 Apr; 50(2):488-494. PubMed ID: 28546525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Predictors of Hypertension Development With Pazopanib and Examining Predictive Performance Over Time.
    Kunitake M; Goto A; Sakai Y; Higuchi K; Muto I; Ueda K; Hamada T; Hiraoka K; Murotani K
    In Vivo; 2024; 38(4):1882-1890. PubMed ID: 38936947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib-induced enteritis in a patient with renal cell carcinoma.
    Ariyoshi M; Hayashi R; Takasago T; Yamashita K; Hiyama Y; Yuge R; Urabe Y; Ueno Y; Shimamoto F; Oka S
    Clin J Gastroenterol; 2024 Jun; 17(3):434-440. PubMed ID: 38407743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Campos SM; Brady WE; Moxley KM; O'Cearbhaill RE; Lee PS; DiSilvestro PA; Rotmensch J; Rose PG; Thaker PH; O'Malley DM; Hanjani P; Zuna RE; Hensley ML
    Gynecol Oncol; 2014 Jun; 133(3):537-41. PubMed ID: 24594074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
    Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
    Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review.
    Turjap M; Pelcová M; Gregorová J; Šmak P; Martin H; Štingl J; Peš O; Juřica J
    Ther Drug Monit; 2024 Jun; 46(3):321-331. PubMed ID: 38723115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
    Tannir N; Hammers H; Amin A
    Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.
    Climent MA; Muñoz-Langa J; Basterretxea-Badiola L; Santander-Lobera C
    Crit Rev Oncol Hematol; 2018 Jan; 121():45-50. PubMed ID: 29279098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
    Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
    Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
    [No Abstract]   [Full Text] [Related]  

  • 20. Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma.
    Yu-Li Su H
    Clin Genitourin Cancer; 2018 Apr; 16(2):114-116. PubMed ID: 29329663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.